DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Candesartan cilexetil (Drug); Hydrochlorothiazide (Drug); Candesartan/HCT 32/25 mg (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Michael Klibaner, MD, Study Director, Affiliation: AstraZeneca
Istvan Edes, MD, Principal Investigator, Affiliation: DEOEC Institute of Cardiology


The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.

Clinical Details

Official title: A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).

Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)

Secondary outcome:

The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study

Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Hypertension Control Rate at the End of the Study (Patients With Controlled Sitting SBP and Sitting DBP).

To Describe Safety and Tolerability of the Study Treatments With Regard to Adverse Events Including Those That Lead to Treatment Discontinuation as Well as With Regard to Pulse Rate, Laboratory, Electrocardiographic and Physical Examination Findings.

To Compare Treatment With Candesartan/HCT 32/25 mg to Each of Its Components With Regard to Change From Baseline to Week 8 in Standing DBP and Standing SBP.

To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Control Rate at the End of the Study (Patients With Controlled Sitting DBP Are Defined as Having a Sitting DBP <90 mmHg at the End of the Study).

To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Responder Rate (Decrease in Sitting DBP ≥10 mmHg From Baseline to the End of the Study or a Sitting DBP <90 mmHg at the End of the Study).


Minimum age: 20 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all

of the following criteria:

- Provision of signed Informed Consent

- Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs

(substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo.

- Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2

- Patients will be eligible for randomisation (Visit 4) if they fulfil the following


- Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the

4-week single-blind placebo run-in period. The run-in period should not be shorter than 4 weeks. Exclusion Criteria:

- Pregnant or lactating women, or women of childbearing potential not practising an

adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit 1.

- Secondary or malignant hypertension

- Sitting SBP of 180 mmHg or more

- Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack

within 6 months before enrolment

- Angina pectoris requiring more treatment than short-acting nitrates

- Chronic use of NSAIDs

- Aortic or mitral valve stenosis

- Cardiac failure requiring treatment

- Cardiac arrhythmia requiring treatment

- Gout

- Renal artery stenosis or kidney transplantation

- Intravascular volume depletion

- Hypersensitivity to any component of the investigational products or to any

sulphonamide derived drugs

- Concomitant disease which may interfere with the assessment of the patient

- Past or present alcohol or drug abuse, or any condition associated with poor

compliance that in the opinion of the investigator might affect the patient's participation in the study

- Chronic liver disease

- Concomitant or previous treatment with any other investigational drug within 20 days

of enrolment

- Previous enrolment in the present study

Locations and Contacts

Research Site, Dour, Belgium

Research Site, Gozée, Belgium

Research Site, Hasselt, Belgium

Research Site, Linkebeek, Belgium

Research Site, Marchovelette, Belgium

Research Site, Ronquières, Belgium

Research Site, Saint-Médard, Belgium

Research Site, Steenokkerzel, Belgium

Research Site, Daugavpils, Latvia

Research Site, Ogre, Latvia

Research Site, Riga, Latvia

Research Site, Gozo, Malta

Research Site, Gwardiamangia, Malta

Research Site, Arad, Romania

Research Site, Bucuresti, Romania

Research Site, Iasi, Romania

Research Site, Pitesti, Romania

Research Site, Ploiesti, Romania

Research Site, Targoviste, Romania

Research Site, Timisoara, Romania

Research Site, Moscow, Russian Federation

Research Site, St. Petersburg, Russian Federation

Research Site, Bratislava, Slovakia

Research Site, Levice, Slovakia

Research Site, Lucenec, Slovakia

Research Site, Presov, Slovakia

Research Site, Sahy, Slovakia

Additional Information

Starting date: January 2007
Last updated: November 30, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017